Full text
Earnings transcript
Read the complete earnings call transcript.
REGN
Regeneron Pharmaceuticals, Inc.
$965.63
37.74
(4.07%)
| Exchange: | NASDAQ |
| Market Cap: | 99.4B |
| Shares Outstanding: | 15.364M |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | BiotechnologyView industry performance | |||||
| CEO: | Leonard S. Schleifer | |||||
| Full Time Employees: | 15410 | |||||
| Address: |
| |||||
| Website: | https://www.regeneron.com |
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
Click to read more…
Revenue Segmentation
Revenue by type
Revenue by region
REGN full analysis
Welcome back to MarketSnap. Let's start with something that shouldn't have happened. Friday's session was ugly — the Nasdaq fell almost 3%, tech dropped more than 4%, and the AI names got hammered. And in the middle of all that, Regeneron, a biotech, jumped 13% on its third-quarter report. That is not supposed to happen on a risk-off day. It tells you money is running out of AI and hiding in boring, cash-rich businesses. Regeneron just became one of those…
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 13,117,200 | 14,202,000 | 14,342,900 |
| Gross Profit | 10,872,700 | 12,231,500 | 12,242,200 |
| EBITDA | 4,693,300 | 5,318,000 | 5,818,200 |
| Operating Income | 4,348,600 | 3,990,700 | 3,577,900 |
| Net Income | 3,953,600 | 4,412,600 | 4,504,900 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 33,080,200 | 37,759,400 | 40,558,700 |
| Total Liabilities | 7,107,100 | 8,405,800 | 2,747,600 |
| Total Stockholders Equity | 25,973,100 | 29,353,600 | 31,256,900 |
| Total Debt | 2,702,900 | 2,704,400 | 2,705,900 |
| Cash and Cash Equivalents | 2,730,000 | 2,488,200 | 0 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 4,594,000 | 4,420,500 | 4,978,900 |
| Capital Expenditure | -926,400 | -755,900 | -898,400 |
| Free Cash Flow | 3,667,600 | 3,664,600 | 4,080,500 |
| Net Income | 3,953,600 | 4,412,600 | 4,504,900 |
| Net Change in Cash | -381,600 | -248,800 | 634,700 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 19,793,477.434 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 24,368,982.071 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 22,542,707.167 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 9,202,529.075 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 11,780,011.255 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 10,751,230.486 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 7,372,485.913 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 9,684,330.155 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 8,761,576.580 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 3,472,734.768 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 4,275,499.926 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 3,955,082.840 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 80.680 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 89.170 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 67.890 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 10 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 5 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Accelerating top-line growth and margin expansion. Q3 2026 revenue rose 36% YoY to $5.1 billion, with non-GAAP EPS up 70% to $20.07. Dupixent, EYLEA HD, and Libtayo each posted record net sales; Dupixent alone reached $6.5 billion globally (+35%). TTM gross margin of 85.8% and net margin of 28.5% reflect a high-quality, scalable commercial model.
- Fortress balance sheet with minimal leverage. Debt-to-equity of 0.08 and a current ratio of 3.35 (quick ratio 2.89) provide substantial financial flexibility. FY2025 free cash flow of $4.08 billion (up from $3.66 billion in FY2024) funds internal R&D and business development without external financing needs.
- Diversified, de-risked pipeline with near-term catalysts. Positive Phase 3 OPTIMA data (84-week sustained efficacy for Pasatru in FOP), ovarian cancer and muscle-preservation trial data, and a weight-loss candidate that halved muscle loss in combination with Novo's semaglutide. The company is preparing multiple large registrational programs across myeloma, anticoagulation, and obesity.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates REGN intrinsic value between $1,110.24 – $1,118.99 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about REGN valuation
Is Regeneron Pharmaceuticals, Inc. (REGN) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for Regeneron Pharmaceuticals, Inc. (REGN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is REGN a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether REGN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is REGN’s P/E ratio?
You can see REGN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for REGN?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is REGN a good long-term investment?
Whether REGN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
REGN
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
4.07
Trading Metrics:
| Open: | 927.22 | Previous Close: | 927.89 | |
| Day Low: | 927 | Day High: | 974 | |
| Year Low: | 591.52 | Year High: | 974 | |
| Price Avg 50: | 793.3 | Price Avg 200: | 737.54 | |
| Volume: | 1.086M | Average Volume: | 737443 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
